Get the Stockscreener App
32.88
2.26%
-0.76
Castle Biosciences Inc stock is traded at $32.88, with a volume of 479.77K.
It is down -2.26% in the last 24 hours and up +12.02% over the past month.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
See More
Previous Close:
$33.64
Open:
$35.84
24h Volume:
479.77K
Relative Volume:
1.18
Market Cap:
$921.28M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-9.8149
EPS:
-3.35
Net Cash Flow:
$-19.25M
1W Performance:
-2.67%
1M Performance:
+12.02%
6M Performance:
+35.14%
1Y Performance:
+82.86%
1-Day Range:
$32.40
$35.84
1-Week Range:
$32.13
$35.84
52-Week Range:
$16.20
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences (NASDAQ:CSTL) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Castle Biosciences' revenue growth leads Canaccord to reaffirm $42 stock PT - Investing.com UK
Castle Biosciences (NASDAQ:CSTL) Reaches New 52-Week High After Earnings Beat - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Given New $39.00 Price Target at Robert W. Baird - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Call Transcript - Insider Monkey
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Castle Biosciences reports robust Q3 growth, raises guidance By Investing.com - Investing.com Canada
Castle Biosciences Reports Strong Q3 2024 Growth - TipRanks
Castle Biosciences Inc (CSTL) Reports Q3 2024 Earnings: Revenue Hits $85.8 Million, Net Income at $2.3 Million - GuruFocus.com
Castle Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Castle Biosciences Reports Third Quarter 2024 Results - Business Wire
Harbor Capital Advisors Inc. Acquires 15,200 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue? - MSN
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: W - GuruFocus.com
Castle Biosciences (NASDAQ:CSTL) Trading Down 3.8%Here's Why - MarketBeat
Castle Biosciences stock soars to 52-week high of $34.55 By Investing.com - Investing.com Canada
Castle Biosciences stock soars to 52-week high of $34.55 - Investing.com
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients - The Bakersfield Californian
The Analyst Landscape: 4 Takes On Castle Biosciences - Benzinga
Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $42.00 - MarketBeat
Why Castle Biosciences decided to build new headquarters in Friendswood - The Business Journals
Castle Biosciences to Participate in Upcoming Investor Conferences - The Bakersfield Californian
Castle Biosciences (CSTL) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Castle Biosciences To Report Q2 Results Next Month - RTTNews
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going - MSN
Castle Biosciences, Inc. (NASDAQ:CSTL) Stake Lowered by SG Americas Securities LLC - MarketBeat
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy? - MSN
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors - Business Wire
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out? - MSN
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength? - MSN
CSTLCastle Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Castle Biosciences CEO Derek Maetzold sells stock for $165,463 By Investing.com - Investing.com South Africa
Castle Biosciences CEO Derek Maetzold sells stock for $165,463 - Investing.com India
Castle Biosciences, Inc. (NASDAQ:CSTL) Sees Significant Drop in Short Interest - MarketBeat
Derek J. Maetzold Sells 1,972 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences Inc (CSTL) deserves closer scrutiny - US Post News
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential - Business Wire
Potential Price Increase for Castle Biosciences Inc (CSTL) After Recent Insider Activity - Knox Daily
Castle Biosciences Inc Inc. (CSTL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Castle Biosciences (NASDAQ:CSTL) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%? - Simply Wall St
Castle Biosciences price target raised to $40 from $35 at BTIG - Yahoo Finance
Castle Biosciences (NASDAQ:CSTL) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $40.00 - MarketBeat
Castle Biosciences stock soars to 52-week high of $32.55 - Investing.com India
Castle Biosciences stock soars to 52-week high of $32.55 By Investing.com - Investing.com UK
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024 - Business Wire
Castle Biosciences (NASDAQ:CSTL) Shares Up 7.3%What's Next? - MarketBeat
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin - Business Wire
Castle Biosciences CEO sells over $77k in company stock By Investing.com - Investing.com South Africa
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):